New MenaQ7® Full Spectrum K2 is the closest ingredient to dietary cheese intake

 

OSLO, NORWAY AND EDISON, NJ (APRIL 17, 2018) — NattoPharma is eager to announce that
Nutrients has published a new paper1, “Menaquinone Content of Cheese”, which examines the Vitamin K2
content of cheeses and other foods. Based on a global state of K2 deficiency and the strong evidence
showing it is a cardio-protective nutrient, researchers recommend cheese as a component of a hearthealthy
diet due to its Vitamin K2 content. But for those unable to consume enough cheese daily,
NattoPharma has introduced its MenaQ7® Full Spectrum K2, which delivers the range of menaquinones
found in foods.

The analysis was conducted by the expert researchers at VitaK, Maastricht University (the Netherlands).
Vitamin K2 (menaquinone) concentrations were measured in a range of cheeses and the effects of fat
content, ripening, and cheese origins were investigated. According to researchers: “It was found that
cheese and curd are the most important sources of long-chain menaquinones in the Western diet.
However, the actual menaquinone content varies substantially and is dependent on the type of cheese,
the time of ripening, the fat content, and the geographic area where the cheeses are produced.”

The findings showed that the total amount of K2 in cheese was between 3 and 802 ng/g. To that end, the
researchers’ recommendation for K2 is between 180-360mcg/day, which means one needs to eat at least
225/445g of French cheese a day (Münster) and at least two times more with cheese from Scandinavia.

In the past decade, increasing attention has been paid to the health benefits of the K2, notably the longchain
menaquinones MK-6 through MK-9. This research adds to important population-based studies2-4
that have shown that food-derived vitamin K (such as from cheeses) improves long-term cardiovascular
health outcomes because it more specifically delivers the spectrum of long-chain menaquinones.

“Interestingly, Vitamin K2 was first discovered in the fermented soy food called natto,” says Hogne Vik,
Chief Medical Officer with NattoPharma. “However, in the early 2000s the researchers working with
NattoPharma discovered that fermented cheese is also an excellent source of the menaquinones, ranging
from menaquinones 5 through 10, while menaquinones 6, 7, and 9 are amongst the most bioactive.”

While fermented cheeses are the best dietary source of menaquinones in the West, most cannot consume
enough daily to obtain optimal amounts of Vitamin K2, nor is cheese a practical source for extracting the
menaquinones. To that end, NattoPharma has introduced MenaQ7® Full Spectrum K2, raw material unlike
anything on the market that delivers the range of menaquinones found in foods.

The first and only Vitamin K2 to deliver a gamut of menaquinone isomers, MenaQ7® Full Spectrum is
naturally fermented using chickpea protein, offering an all-trans K2 that is free from gluten, soy and allknown
allergens, and is suitable for vegans. MenaQ7® Full Spectrum provides the vital menaquinone
isomers for optimal K2 delivery with respect to absorption, half-life and biological activity.

“NattoPharma has once again created a raw material that speaks directly the natural dietary supplement
consumer, who is drawn to comprehensive nutritional sources,” adds Eric Anderson, NattoPharma Senior
Vice President of Marketing and Business Development. “No other material on the market offers such a
comprehensive array of menaquinones specifically shown to support cardiovascular health. MenaQ7 Full
Spectrum is the closest ingredient to actual food sources, delivering the range of menaquinones found in
foods that support cardiovascular health.”

References:
1 Vermeer C, et al. Menaquinone Content of Cheese. Nutrients. Apri 4;10(4). Pii: E446 doi: 10.3390/nu10040446.
2 Geleijnse JM, et al. Dietary intake of menaquinone is associated with a reduced risk of coronary heart disease: the
Rotterdam Study. J Nutr. 2004;134:3100-5.
3 Beulens JW, et al. High dietary menaquinone intake is associated with reduced coronary calcification.
Atherosclerosis. 2009;203:489-93.
4 Gast GC, et al. A high menaquinone intake reduces the incidence of coronary heart disease. Nutr Metab
Cardiovasc Dis. 2009;19:504-10.

XXX

About NattoPharma and MenaQ7®
NattoPharma ASA, based in Norway, is the world’s leader in vitamin K2 research and development. NattoPharma is
the exclusive international supplier of MenaQ7® Vitamin K2 as MK-7, the best documented, vitamin K2 as
menaquinone-7 (MK-7) with guaranteed actives and stability, clinical substantiation, and international patents
granted and pending; and now the new MenaQ7® Full Spectrum, which delivers menaquinones 6, 7, and 9. The
company has a multi-year research and development program to substantiate and discover the health benefits of
Vitamin K2 for applications in the marketplace for functional food and dietary supplements. With a global presence,
the company established its North American subsidiary, NattoPharma USA, Inc., in Edison, NJ, and NattoPharma
R&D Ltd. in Cyprus. For more information, visit www.nattopharma.com or www.menaq7.com.

For more information, please contact:
Kate Quackenbush, NattoPharma Communications Director; E-mail: kate.quackenbush@nattopharma.com